Neos Therapeutics Inc. (NASDAQ:NEOS) was down 3.8% on Thursday . The company traded as low as $8.70 and last traded at $8.76, with a volume of 56,036 shares. The stock had previously closed at $9.11.

A number of equities research analysts have weighed in on NEOS shares. BMO Capital Markets reiterated a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a report on Tuesday, July 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. Zacks Investment Research upgraded Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Thursday, April 21st. Finally, Royal Bank Of Canada decreased their price objective on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $21.75.

The stock’s market capitalization is $139.75 million. The company’s 50 day moving average is $9.24 and its 200-day moving average is $9.78.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Monday, May 16th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.08. Analysts expect that Neos Therapeutics Inc. will post ($4.88) EPS for the current year.

In related news, Director Gregory J. Robitaille bought 7,442 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The stock was bought at an average cost of $7.55 per share, for a total transaction of $56,187.10. Following the acquisition, the director now directly owns 55,677 shares of the company’s stock, valued at approximately $420,361.35. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan L. Heller bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The shares were bought at an average price of $7.61 per share, with a total value of $76,100.00. Following the completion of the acquisition, the director now directly owns 379,888 shares in the company, valued at $2,890,947.68. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP increased its stake in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.